Junia V. Melo

The molecular biology of chronic myeloid leukemia

Michael W. Deininger, John M. Goldman, Junia V. Melo · Blood · 2000 · 1.6K citations

Medicine, Molecular Biology, Oncology +14

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

François Xavier Mahon, Michael W. Deininger, Beate Schultheis et al. · Blood · 2000 · 760 citations

Medicine, Molecular Biology, Oncology +15

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

David M. Ross, Susan Branford, John F. Seymour et al. · Blood · 2013 · 706 citations

Medicine, Immunology, Pharmacotherapy +11

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

Jane F. Apperley, Martine Gardembas, Junia V. Melo et al. · New England Journal of Medicine · 2002 · 631 citations · Full text

Medicine, Hematology, Molecular Genetics +16

The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells

Michael W. Deininger, John M. Goldman, Nicholas Lydon et al. · Blood · 1997 · 626 citations

Life Sciences, Oncology, Pharmacology +10